Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of melanoma (International Classification of Diseases 9th or 10th Revision Clinical Modification - ICD-9-CM: 172.X; ICD-10-CM: C43.x) and secondary malignancy or metastasis (ICD-9-CM: 196.x, 197.x, 198.x; ICD-10-CM: C77.x, C78.x, C79.x).
Confirmed BRAF V600E/V600K activating mutation reported in the data based on laboratory or genetic analysis results.
At least 1 order or administration of ENCO+BINI treatment
You may not be if
Patients without information on mortality
Patients with ECOG performance status ≥ 2 (at the time of randomization for patients from COLUMBUS, during the baseline period for patients in Flatiron Electronic Health Record)
Clareo Health | A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
